Updated Mar 7, 2026 · 2187 articles
Insights
Research, news and field guides on institutional positioning. Powered by real SEC filings — 13F, 13D/G, Form 4.
How to Use 1%, 3%, 5%, and 10% Position Weights in 13F Analysis
Position-weight thresholds help you separate noise from genuine conviction. Here is a practical way to use 1%, 3%, 5%, and 10% in 13F reading.
Sarah MitchellHow to Read Sector ETF Signals Without Overstating the Bet
A sector ETF line like XLK can matter, but only in proportion to the full portfolio. Here is how to read those signals without exaggerating them.
Sarah MitchellGiant Filers Spread Top-Ten Exposure From 26% to 36% in Q4 2025
JPMorgan, Vanguard, Capital World Investors, and FMR all own the market leaders, but their top-ten concentration ranges from 26.3% to 36.4%, creating very different portfolio behavior.
Marcus ChenMitchell Jacobson Bought Roughly $17M of MSC Industrial After a Weak 2025 and a Leadership Reset
Mitchell Jacobson bought about $17.2 million of MSC Industrial stock in late 2025 after a weak operating stretch, a CFO transition, and a difficult year for the distribution business.
Alex RiveraHow to Compare Mega-Filers With Boutique Managers Without Getting Misled by Scale
Raw dollars make giant filers look more decisive than they really are. Percentage weight, concentration, and portfolio role are better comparison tools.
Sarah MitchellHow to Read Options-Heavy 13Fs Without Confusing Exposure and Conviction
Options-heavy 13Fs can look extremely bullish or bearish on the surface. The right reading is usually subtler: they often express payoff design, not pure stock conviction.
Sarah MitchellWhat a New QQQ or XLK Position Really Signals in a 13F
A new QQQ or XLK line often means more than simple tech optimism. It can mark a deliberate factor, sector, or timing overlay on top of a broader portfolio.
Sarah MitchellHow to Tell If a Fund Is Benchmarking or Actually Tilting
Some 13F portfolios mostly mirror the market. Others add real style or thematic tilts on top. Here is how to tell the difference quickly.
Sarah MitchellHow to Read Bond and Cash ETF Sleeves Inside a 13F
Bond and short-duration ETF positions often reveal how cautious or balanced a manager really is. Here is how to read those sleeves instead of skipping past them.
Sarah MitchellHow to Use 13F and Form 4 Together to Build a Better Investment Thesis
13F filings tell you what institutions are doing. Form 4 filings tell you what insiders are doing. The real edge comes from reading both together without forcing them to mean the same thing.
Sarah MitchellPrecigen 10% Owner Randal Kirk Sold About $45.1M After PAPZIMEOS Won FDA Approval
Randal Kirk's September-to-December Precigen selling followed a major corporate milestone: FDA approval of PAPZIMEOS, the company's first approved product in the U.S., and new long-term follow-up messaging around the platform.
Alex RiveraWhat Top-Five Concentration Really Tells You About a Fund
Top-five concentration is one of the fastest ways to see whether a 13F belongs to an allocator, a concentrated stock picker, or something in between.
Sarah MitchellHow to Read ETF-Heavy 13F Filings When the Signal Is Allocation, Not Stock Picking
Some 13F filings are not trying to tell you which stock will win. They are telling you how a manager is allocating risk across broad markets, factors, income, and growth.
Sarah MitchellCiena CEO Gary Smith Sold About $23.2M of CIEN Stock After AI Network Demand Drove a Guidance Raise
Gary Smith's late-December to mid-February Form 4 tape came as Ciena talked about unprecedented AI-related demand, reported $1.43B in fiscal Q1 2026 revenue, and raised full-year guidance.
Alex RiveraSEI Founder Alfred West Sold Roughly $26M in 2025 Before Handing Off the Chair on January 1
Alfred P. West Jr.'s 2025 Form 4 tape culminated in a December exercise-and-sale, then SEI announced his planned transition to Chairman Emeritus and later reported strong Q4 results.
Alex RiveraCastle Biosciences CEO Derek Maetzold Sold About $2.2M of CSTL After a Guidance Raise and a Post-Earnings Rally
Derek Maetzold's November-December Form 4 activity came after Castle Biosciences raised 2025 revenue guidance and the stock surged on the Q3 release, making this a post-strength sell pattern rather than a panic exit.
Alex RiveraHow to Compare Two 13F Filers Without Getting Fooled by AUM
The biggest portfolio is not always the most useful one to study. To compare two 13F filers well, you need to normalize for size, concentration, turnover, and what each filing is actually built to do.
Sarah MitchellMario Gabelli Put Roughly $66M Into His Own Closed-End Complex as the 2026 Distribution and Rights Cycle Began
Mario Gabelli's recent Form 4 tape is a closed-end fund rotation story, not a simple one-stock buy: heavy December purchases in GDV, GAB, GRX, and related vehicles followed by January-February follow-through.
Alex RiveraWhy Put Options Show Up in 13F Filings and What They Don't Mean
A put option in a 13F is not the same thing as a simple bearish bet. Without context, many investors overstate what an options line really says about risk and direction.
Sarah MitchellHow to Read 13F Position Changes: New, Added, Trimmed, and Exited
Most investors jump straight to the holdings table. The better habit is to read what changed: which positions are new, which got bigger, which were cut, and which disappeared entirely.
Sarah Mitchell